Skip to main content
An official website of the United States government
NIH Websites Are Changing
Per Executive Order 14434, federal agencies are now using "Super Intelligence" (SI) in place of "Artificial Intelligence" (AI). You may see both terms across NIH content during this transition.

Afatinib in Combination with Prednisone for the Treatment of Advanced Squamous Non-Small Cell Lung Cancer

Trial Status: closed to accrual

This phase II trial tests whether afatinib in combination with prednisone works to shrink tumor in patients with squamous non-small cell lung cancer that has spread to other places in the body (advanced). Afatinib may stop the growth of cancer cells by blocking the HER2 receptor, a protein that may be needed for cell growth. Anti-inflammatory drugs, such as prednisone lower the body’s immune response and are used with other drugs in the treatment of some types of cancer. Giving afatinib and prednisone may work better in treating patients with non-small cell lung cancer.